Nyxoah S.A.
NYXH · Healthcare · $137M
$1.37-13.84%
Price
$1.78
$1.37
Jul 1, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
6/'26
Revenue$9M+3.0%
Operating Income-$23M+14.4%
Net Income-$38M-76.9%
3/'26 vs prev quarter
Company Health
Market Cap$137M
Operating Margin-384.2%
Cash on Hand$112M81.5% of market cap
Free Cash Flow$-86M-62.5% of market cap
Among 16 Medical - Specialties peers
LowMedianHigh
PSR5.2xmedian 3.0xPBR1.4xmedian 1.7xROE-120.3%median -27.2%Nyxoah Appoints Liam Kelly as Chief Executive OfficerYesterday
Nyxoah Announces Chief Financial Officer TransitionSep 21
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE TrialSep 8
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® SystemSep 7
Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®Sep 7
Nyxoah SA (NYXH) Q2 2026 Earnings Call TranscriptAug 5
